Moderna Inc (NAS:MRNA)
$ 141.01 8.11 (6.1%) Market Cap: 54.04 Bil Enterprise Value: 43.65 Bil PE Ratio: 0 PB Ratio: 4.21 GF Score: 68/100

Moderna Inc to Discuss New Interim Clinical Data About mRNA Vaccine Against COVID-19 - Conference Call Transcript

Aug 26, 2020 / 08:30PM GMT
Release Date Price: $70.5 (+6.42%)
Operator

Good afternoon and welcome to Moderna's conference call. (Operator Instructions) Please be advised that the call is being recorded.

At this time, I'd like to turn the call over to Lavina Talukdar, Head, Investor Relations at Moderna. Please proceed.

Lavina Talukdar
Moderna, Inc. - Head of IR

Thank you, Gigi. Hello, everyone. Hope you are all well, and thank you for joining us this afternoon or late night, depending on where you're dialing in from. On today's conference call, we will discuss our Phase I interim results from the older adult cohorts for mRNA-1273, our vaccine against COVID-19. You can access the press release issued today as well as the slides that we'll be reviewing by going to the Investors section of our website.

Speaking on today's call are Stéphane Bancel, our Chief Executive Officer; Tal Zaks, our Chief Medical Officer; Juan Andres, our Chief Technical and Manufacturing Officer; and David Meline, our Chief Financial Officer.

Before we begin, note that this conference call will include forward-looking statements

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot